Cytora

Company Overview

Snapshot

Founded in April 2015 by Jacob Zankel and Prof. Sandu Pitaru, Cytora operates with 11–50 employees. The company has raised $2M across two funding rounds from two investors. In August 2024, Cytora secured a grant from the Israel Innovation Authority.

Business overview

Cytora is a clinical-stage biotechnology company focused on developing allogeneic stem cell therapies derived from human oral mucosa stem cells (hOMSC). The company aims to provide off-the-shelf stem cell medicines for challenging diseases such as Parkinson’s, Multiple System Atrophy (MSA), Alzheimer’s Dementia, and non-healing diabetic wounds. Cytora's core technology leverages these unique stem cells to address significant unmet medical needs within the Health Tech & Life Sciences sector, specifically targeting Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In May 2026, Cytora appointed Dr. Thomas Serena, a renowned wound care expert, to its Scientific Advisory Board. This strategic addition is poised to accelerate patient treatment access and data collection for Cytora's hOMSC therapy, particularly for non-healing diabetic wounds. This signals a strong commitment to clinical advancement and market penetration, indicating a forward trajectory towards commercialization and broader patient impact.

Company Intelligence Q&A

What is Cytora's core therapeutic focus?

Cytora is developing allogeneic stem cell therapies using human oral mucosa stem cells (hOMSC) to treat severe conditions like Parkinson’s, Multiple System Atrophy, Alzheimer’s Dementia, and non-healing diabetic wounds.

What was a key recent development in Cytora's clinical trials?

In April 2025, Cytora reported successful results from its Phase 1/2a trial for a stem cell treatment targeting diabetic foot ulcers.

Who joined Cytora's Scientific Advisory Board in May 2026?

In May 2026, Cytora appointed Dr. Thomas Serena, a world-renowned wound care expert, to its Scientific Advisory Board to lead patient treatment access and data collection for its hOMSC therapy.

Has Cytora received any non-equity funding recently?

In August 2024, Cytora secured a grant from the Israel Innovation Authority for proof-of-concept development.

Which investors participated in Cytora's January 2018 funding round?

In January 2018, Cytora received funding from Net Capital Ventures and G.O Innovation.